SHE: 300601

Biohaven Licenses MoDE Pan‑IgG Degrader Portfolio to Ono Pharmaceutical in Asia – Up to USD 100 Million in Near‑Term Payments for BHV‑1300 Franchise
CompanyDeals

Biohaven Licenses MoDE Pan‑IgG Degrader Portfolio to Ono Pharmaceutical in Asia – Up to USD 100 Million in Near‑Term Payments for BHV‑1300 Franchise

Biohaven Ltd. (NYSE: BHVN) announced that it has entered into a strategic licensing and collaboration agreement with Japan's Ono Pharmaceutical Co., Ltd. (TYO: 4528). Under the agreement, Ono will obtain…

Mirxes Partners with Thailand's National Cancer Institute on Blood‑Based Colorectal Cancer Screening – 2,000‑Subject Prospective Triage Study Backs "Cancer Moonshot 2056"

Mirxes Partners with Thailand’s National Cancer Institute on Blood‑Based Colorectal Cancer Screening – 2,000‑Subject Prospective Triage Study Backs “Cancer Moonshot 2056”

Huadong Medicine's Doer Bio Wins NMPA Clearance to Trial DR30206 – Tri‑Target PD‑L1/VEGF/TGF‑β Fusion Protein Advances into Stage III NSCLC Consolidation Therapy

Huadong Medicine’s Doer Bio Wins NMPA Clearance to Trial DR30206 – Tri‑Target PD‑L1/VEGF/TGF‑β Fusion Protein Advances into Stage III NSCLC Consolidation Therapy

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Kangtai Biological's Pentavalent Rotavirus Vaccine Enters Phase III Trials
CompanyDrug

Kangtai Biological’s Pentavalent Rotavirus Vaccine Enters Phase III Trials

Shenzhen Kangtai Partners with AstraZeneca to Establish Vaccine JV in Beijing
CompanyDeals

Shenzhen Kangtai Partners with AstraZeneca to Establish Vaccine JV in Beijing

Shenzhen Kangtai Halts COVID-19 Vaccine Development Amid Market Shifts
CompanyDrug

Shenzhen Kangtai Halts COVID-19 Vaccine Development Amid Market Shifts

Shenzhen Kangtai Begins Phase I Clinical Trial for 20-Valent Pneumococcal Vaccine
CompanyDrug

Shenzhen Kangtai Begins Phase I Clinical Trial for 20-Valent Pneumococcal Vaccine

CompanyDrug

Kangtai Biological Receives NMPA Approval for 20-Valent Pneumococcal Vaccine Clinical Trial

CompanyDeals

Kangtai Biological Partners with AstraZeneca and Beijing Daxing District to Boost Vaccine Market Presence

CompanyDeals

Kangtai Biological Products Co., Ltd. Expands Vaccine Access in South Asia with Bangladesh Deal

CompanyDeals

Kangtai Biological Partners with Bahrain Pharma Firm on Strategic Vaccine Production Agreement

Show More